Pursuant to a resolution passed by shareholders on Nov. 5, 2014, in connection with the amalgamation agreement, the company has consolidated its capital on a one-new-for-five-old basis. The name of the company has also been changed from Technical Ventures RX Corp. to Hemostemix Inc.

Effective at the opening on Thursday, Nov. 27, 2014, the common shares of Hemostemix will commence trading on the TSX Venture Exchange and the common shares of Technical Ventures RX will be delisted.

The company is classified as a pharmaceuticals company.

Postconsolidation

Capitalization:  Unlimited common shares with no par value, of which 65,172,119 common shares are issued and outstanding

Escrow:  18,871,454 common shares are subject to escrow, of which 18,465,454 shares are subject to a Tier 2 value escrow agreement and 406,000 shares remain subject to a CPC escrow agreement

Transfer agent:  Computershare Trust Company of Canada

Trading symbol:  HEM (new)

Cusip No.:  423694 10 8 (new)